Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Opportunities to Optimize Cancer Policies Panel Discussion

Welcome and Introduction to Vi3C

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Sep

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Opportunities to Optimize Cancer Policies Panel Discussion

Welcome and Introduction to Vi3C

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC

FDA Advisory Committee Votes In Favor of Approval of Multi-Cancer Early Detection Test

New AI Model Outperforms Oncotype DX for Predicting Recurrence Risk in Breast Cancer

CAP Updates Cancer Protocols for Breast Cancer Biomarker Reporting and GIST Molecular Testing

Robert Kyle Myeloma Expert Dies at 98